Enhertu shows positive results in DESTINY-Breast06 Phase III trial EP News Bureau Apr 29, 2024 Demonstrates statistically significant and clinically meaningful improvement in progression-free survival in HR-positive, HER2-low…
FDA approves Verzenio as the first and only CDK4/6 inhibitor for certain people with HR+HER2-… EP News Bureau Oct 14, 2021 Verzenio phase-III monarchE trial is a randomised (1:1), open-label, two cohort, multi-centre study in adult women and men with…
